Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

GLPG

Galapagos (GLPG)

Galapagos
Date:
Sort by:
 Showing the most relevant articles for your search:EU:GLPG
DateTimeSourceHeadlineSymbolCompany
01/08/202512:30AMGlobeNewswire Inc.Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded EntitiesEU:GLPGGalapagos
01/07/20253:01PMGlobeNewswire Inc.Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceEU:GLPGGalapagos
12/07/202411:30AMGlobeNewswire Inc.Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin LymphomaEU:GLPGGalapagos
11/05/20243:01PMGlobeNewswire Inc.Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024EU:GLPGGalapagos
10/30/20243:01PMGlobeNewswire Inc.Galapagos Reports Third Quarter 2024 Financial Results and Provides Business UpdateEU:GLPGGalapagos
10/07/202412:00AMGlobeNewswire Inc.Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growthEU:GLPGGalapagos
09/30/20243:01PMGlobeNewswire Inc.Galapagos receives transparency notification from EcoR1 CapitalEU:GLPGGalapagos
09/16/20243:01PMGlobeNewswire Inc.Galapagos receives transparency notification from EcoR1 CapitalEU:GLPGGalapagos
09/03/20243:01PMGlobeNewswire Inc.Galapagos receives transparency notification from FMR LLCEU:GLPGGalapagos
08/23/202412:00AMGlobeNewswire Inc.Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphomaEU:GLPGGalapagos
08/20/20243:01PMGlobeNewswire Inc.Galapagos receives transparency notification from FMR LLCEU:GLPGGalapagos
08/01/20243:01PMGlobeNewswire Inc.Galapagos reports half-year 2024 financial results and provides second quarter business updateEU:GLPGGalapagos
06/14/20243:01PMGlobeNewswire Inc.Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024EU:GLPGGalapagos
06/14/20243:01PMGlobeNewswire Inc.Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024EU:GLPGGalapagos
05/30/20243:01PMGlobeNewswire Inc.Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsEU:GLPGGalapagos
05/30/20243:01PMGlobeNewswire Inc.Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsEU:GLPGGalapagos
05/16/20243:01PMGlobeNewswire Inc.Galapagos creates new subscription right plansEU:GLPGGalapagos
05/16/20243:01PMGlobeNewswire Inc.Galapagos creates new subscription right plansEU:GLPGGalapagos
05/15/20243:01PMGlobeNewswire Inc.Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.EU:GLPGGalapagos
05/15/20243:01PMGlobeNewswire Inc.Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.EU:GLPGGalapagos
05/02/20243:01PMGlobeNewswire Inc.Galapagos reports first quarter 2024 financial results  EU:GLPGGalapagos
05/02/20243:01PMGlobeNewswire Inc.Galapagos reports first quarter 2024 financial results  EU:GLPGGalapagos
04/30/20243:01PMGlobeNewswire Inc.Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024EU:GLPGGalapagos
04/30/20243:01PMGlobeNewswire Inc.Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024EU:GLPGGalapagos
04/04/20243:01PMGlobeNewswire Inc.Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024EU:GLPGGalapagos
04/04/20243:01PMGlobeNewswire Inc.Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024EU:GLPGGalapagos
03/28/20243:01PMGlobeNewswire Inc.Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ MeetingsEU:GLPGGalapagos
03/28/20243:01PMGlobeNewswire Inc.Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ MeetingsEU:GLPGGalapagos
03/26/20243:01PMGlobeNewswire Inc.Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its BoardEU:GLPGGalapagos
03/26/20243:01PMGlobeNewswire Inc.Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its BoardEU:GLPGGalapagos
 Showing the most relevant articles for your search:EU:GLPG